Stay updated on Pegilodecakin Combo vs Pembrolizumab Alone in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pegilodecakin Combo vs Pembrolizumab Alone in NSCLC Clinical Trial page.

Latest updates to the Pegilodecakin Combo vs Pembrolizumab Alone in NSCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedRevision tag updated from v3.5.3 to v3.5.4. This represents a minor update to the page's revision history rather than a substantive content change.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe page footer revision marker was updated to **Revision: v3.5.3** (from **v3.5.2**), reflecting an interface/version change rather than any study-record information.SummaryDifference0.0%

- Check39 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check68 days agoChange Detected- Revision: v3.5.0 was added and Revision: v3.4.3 was removed.SummaryDifference0.0%

- Check83 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check105 days agoChange DetectedRevision: v3.4.2 added; prior notice about government funding status (v3.4.1) was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to Pegilodecakin Combo vs Pembrolizumab Alone in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pegilodecakin Combo vs Pembrolizumab Alone in NSCLC Clinical Trial page.